Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetes Therapy
Published in: Diabetes Therapy 4/2016

Open Access 01-12-2016 | Original Research

Medication Adherence Contributes to an Improved Quality of Life in Type 2 Diabetes Mellitus Patients: A Cross-Sectional Study

Authors: Sofa D. Alfian, Hadyana Sukandar, Keri Lestari, Rizky Abdulah

Published in: Diabetes Therapy | Issue 4/2016

Login to get access

Abstract

Introduction

Diabetes mellitus is a chronic disease with a high prevalence world wide. This disease has also been reported to affect the quality of life (QOL) of the patient and their family due to its chronic nature and multi organ involvement. The aim of this study was to analyze the association between adherence to prescribed diabetes medication and diabetes-specific QOL in patients attending Secondary Health Care Facility in Bandung City, Indonesia.

Methods

A cross-sectional survey was conducted in the Secondary Health Care Facility in Bandung City, Indonesia. Data were collected between February and April 2014 using consecutive sampling. Adherence was assessed using the eight-item Morisky Medication Adherence Scale while diabetes-specific-QOL was assessed using the Diabetes 39 instrument.

Results

The results showed that among the patients, 49.4% exhibited low adherence, 29.7% exhibited medium adherence, and 20.9% exhibited high adherence to diabetes medication. Diabetes-specific QOL proved to be highly affected in the sexual functioning domain. Social-burden domain scores were better than overall QOL scores. There was a significant association between adherence and diabetes-specific QOL (p = 0.009) using The Kruskall-Wallis test of significance. The results of the post hoc Mann–Whitney tests (high vs medium adherence, p = 0.084; medium vs low adherence, p = 0.86; and high vs low adherence, p = 0.001) indicated that higher adherence to prescribed diabetes medication contributed to an improved QOL. Multiple regression analysis showed that the predictors of diabetes-specific QOL were adherence and patient income.

Conclusions

Adherence to prescribed medication showed a positive effect on diabetes-specific QOL in patients. Patients with a high adherence to medication had an improved QOL. This result is important not only in developing intervention programs for patients but also in improving their QOL through sustainable health promotion.
Literature
1.
Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.CrossRefPubMed
2.
3.
Huang I, Hwang CC, Wu MY, Lin W, Leite W, Wu AW. Diabetes-specific or generic measures for health-related quality of life? evidence from psychometric validation of the D-39 and SF-36. Value Health. 2008;11(3):450–61.CrossRefPubMed
4.
5.
World Health Organization. Adherence to long term therapies: evidence for action. 2003. pp. 7–9.
6.
Wroth TH, Pathman DE. Primary medication adherence in a rural population: the role of the patient-physician relationship and satisfaction with care. J Am Board Fam Med. 2006;19(5):478–86.CrossRefPubMed
7.
Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218–24.CrossRefPubMed
8.
Shim YT, Lee J, Toh MP, Tang WE, Ko Y. Health-related quality of life and glycaemic control in patients with type 2 diabetes mellitus in singapore. Diabet Med. 2012;29(8):241–8.CrossRef
9.
Farias MS, Agra CC, Araújo LK, Correia DS, Cavalcante JC. Treatment adherence and life quality of diabetic patients assisted in the primary care division. Rev Soc Bras Clín Med. 2014;12(2):102–7.
10.
Gimenes HT, Zanetti ML, Haas VJ. Factors related to patient adherence to antidiabetic drug therapy. Rev Latino Am Enfermagem. 2009;17(1):46–51.CrossRef
11.
Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2012;156(3):218–31.CrossRefPubMed
12.
Anderson RM, Fitzgerald JT, Wisdom K, Davis WK, Hiss RG. A comparison of global versus disease-specific quality-of-life measures in patients with NIDDM. Diabetes Care. 1997;20(3):299–305.CrossRefPubMed
13.
Watkins K, Connel CM. Measurement of health related QOL in diabetes mellitus. Pharmacoeconomics. 2004;22:1109–26.CrossRefPubMed
14.
El Achhab Y, Nejjari C, Chikri M, Lyoussi B. Disease-specific health-related quality of life instruments among adults diabetic: a systematic review. Diabetes Res Clin Pract. 2008;80(2):171–84.CrossRefPubMed
15.
Lee LJ, Fahrbach JL, Nelson LM, McLeod LD, Martin SA, Sun P, Weinstock RS. Effects of insulin initiation on patient-reported outcomes in patients with type 2 diabetes: results from the DURABLE trial. Diabetes Res Clin Pract. 2010;89(2):157–66.CrossRefPubMed
16.
17.
Bangun AV. Faktor-faktor yang Berkontribusi terhadap Kepatuhan Pasien DM Tipe 2 dalam Konteks Asuhan Keperawatan di Poliklinik Endokrin RS Hasan Sadikin Bandung. Jakarta: Universitas Indonesia; 2009.
18.
Morisky DE, Ang A, Krousel-Wood MA, Ward H. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Pharm. 2008;10:348–54.
19.
Krapek K, King K, Warren SS, George KG, Caputo DA, Mihelich K, et al. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother. 2004;38:1357–62.CrossRefPubMed
20.
Zulian LR, Santos MA, Veras VS, Rodrigues FFL, Arrelias CCA, Zanetti ML. Quality of life in patients with diabetes using the Diabetes 39 (D-39) instrument. Rev Gaúcha Enferm. 2013;34(3):138–46.CrossRefPubMed
21.
Boccuzzi SJ, Wogen J, Fox J, Sung JCY, Shah AB, Kim J. Utilization of oral hypoglycemic agents in a drug-insured US population. Diabetes Care. 2001;24:1411–5.CrossRefPubMed
22.
Abdulah R, Barliana M, Pradipta IS, Halimah E, Diantini A, Lestari K. Assessment of patient care indicators at community pharmacies in Bandung City, Indonesia. Southeast Asian J Trop Med Public Health. 2014;45(5):1196–201.PubMed
23.
Insani WN, Lestari K, Abdulah R, Ghassani SK. Effect of Pharmaceutical Information Care on Clinical Outcomes of Patients with Type 2 Diabetes Mellitus. Indonesian J Clin Pharm. 2013;2(4):127–35.
24.
Carey MP, Jorgensen RS, Weinstock RS, Sprafkin RP, Lantinga LJ, Carnrike CL, Baker MT, Meisler AW. Reliability and validity of the appraisal of diabetes scale. J Behav Med. 1991;14(1):43–51.CrossRefPubMed
25.
Hammond GS, Aoki TT. Measurement of Health Status in diabetic patients: diabetes impact measurement scales. Diabetes Care. 1992;15(4):469–77.CrossRefPubMed
26.
Bott U, Mühlhause I, Overmann H, Berger M. Validation of a diabetesspecific quality-of-life scale for patients with type 1 diabetes. Diabetes Care. 1998;21(5):757–69.CrossRefPubMed
27.
Hassan K, Loar R, Anderson BJ, Heptulla RA. The role of socioeconomic status, depression, quality of life, and glycemic control in type 1 diabetes mellitus. J Pediatr. 2006;149(4):526–31.CrossRefPubMed
28.
Puri K, Sapra S, Jain V. Emotional, behavioral and cognitive profile, and quality of life of indian children and adolescents with type 1 diabetes. Indian J Endocrinol Metab. 2013;17(6):1078–83.CrossRefPubMedPubMedCentral
29.
O’Neil KJ, Jonnalagadda SS, Hopkins BL, Kicklighter JR. Quality of life and diabetes knowledge of young persons with type 1 diabetes: influence of treatment modalities and demographics. J Am Diet Assoc. 2005;105(1):85–91.CrossRefPubMed
30.
Alfian SD, Sukandar H, Arisanti N, Abdulah R. Complementary and alternative medicine use decreases adherence to prescribed medication in diabetes patients. Ann Trop Med Public Health. 2016;9(3):174–9.CrossRef
31.
Martinez YV, Prado-Aguilar CA, Rascon-Pacheco RA, Valdivia-Martinez JJ. Quality of life associated with treatment adherence in patients with type 2 diabetes: a cross sectional study. BMC Health Serv Res. 2008;8:164.CrossRefPubMedPubMedCentral
32.
Glasgow RE, Ruggiero L, Eakin EG, Dryfoos J, Chobanian L. Quality of life and associated characteristics in a large national sample of adults with diabetes. Diabetes Care. 1997;20(4):562–7.CrossRefPubMed
33.
Ferrans CE, Powers MJ. Psychometric assessment of the Quality of Life Index. Res Nurs Health. 1992;15(1):29–38.CrossRefPubMed
34.
Goldney RD, Philips PJ, Fisher LJ, Wilson DH. Diabetes, depression, and quality of life. Diabetes Care. 2004;27:1066–70.CrossRefPubMed
35.
Pereira MG, Berg-Cross L, Almeida P, Machado JC. Impact of Family Environment and Support on Adherence, Metabolic Control, and Quality of Life in Adolescents with Diabetes. Int J Behav Med. 2008;15:187–93.CrossRefPubMed
36.
Fitzgerald JT, Gruppen LD, Anderson RM, Funnell MM, Jacober SJ, Grunberger GE, Aman LC. The influence of treatment modality and ethnicity on attitudes in Type 2 diabetes. Diabetes Care. 2000;23:313–8.CrossRefPubMed
37.
De Berardis G. Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked. Diabetes Care. 2002;25(2):284–91.CrossRefPubMed
38.
39.
Hisasue S, Kumamoto Y, Sato Y, Masumori N, Horita H, Kato R, et al. Prevalence of female sexual dysfunction symptoms and its relationship to quality of life: a Japanese female cohort study. Urology. 2005;65:143–8.CrossRefPubMed
Metadata
Title
Medication Adherence Contributes to an Improved Quality of Life in Type 2 Diabetes Mellitus Patients: A Cross-Sectional Study
Authors
Sofa D. Alfian
Hadyana Sukandar
Keri Lestari
Rizky Abdulah
Publication date
01-12-2016
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 4/2016
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-016-0203-x

Other articles of this Issue 4/2016

Diabetes Therapy 4/2016 Go to the issue

Original Research

Simvastatin Rapidly and Reversibly Inhibits Insulin Secretion in Intact Single-Islet Cultures

Original Research

Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2–16 Years

Original Research

Lixisenatide Improves Glycemic Control in Asian Type 2 Diabetic Patients Inadequately Controlled With Oral Antidiabetic Drugs: An Individual Patient Data Meta-Analysis

Commentary

Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial

Original Research

Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes

Letter

Letter to the Editor Regarding: Patterns and Impact of Hypoglycemia, Hyperglycemia, and Glucose Variability on Inpatients with Insulin-Treated Cystic Fibrosis-Related Diabetes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits